Compare Merck & Co., Inc. (MRK) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Wynn Resorts, Limited — how do they compare? Merck & Co., Inc. trades at $126.26 (market cap $307.25B), while Wynn Resorts, Limited trades at $94.75 (market cap $9.93B). The key difference: Merck & Co., Inc. is far larger — about 30.9× Wynn Resorts, Limited's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | WYNN | |
|---|---|---|
Market Cap | $307.25B | $9.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.52 | $133.34 |
52-Week Low | $77.60 | $94.78 |
Enterprise Value | $350.66B | $20.29B |
Dividend Yield | 2.73% | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Wynn Resorts (WYNN) trades at $94.63, down 2.08% today, amid a bearish technical signal with recent earnings misses. The company maintains strong revenue growth with $7.14B in 2025, though net margins have compressed to 4.58%. Recent news highlights operational awards and Q2 2026 earnings anticipation. Technical indicators show support near $93-$95 with resistance at $97-$99, while RSI levels suggest neutral momentum.
Outlook remains mixed: analyst consensus is bullish with a $135.50 price target (64% buy ratings), but high debt ($10.5B long-term) and margin pressure pose risks. The stock offers potential upside if Macau and Las Vegas momentum sustains, though geopolitical and competitive headwinds require monitoring. Near-term catalysts include Q2 earnings on August 4, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
